Tuesday 16 August 2022 - 02:37
PLEASE NOTE: During August 2022 we are doing a comprehensive revision of our customer service workflow. This includes training of current and new personnel. We are expecting that these changes will have only very minimal effects on our overall order processing and shipping activities. However, we do ask any customers who prefer that their shipments go out on Fridays to contact our Customer Service group and let them know about your preferences in advance. Thank you.
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
R-6300 Rucaparib, Free Base, >99%
Synonyms : [AG-14447]
Related Terms : [Rubraca]

- Size
- US $
- €
- £
- ¥
- 5 mg
- 55
- 53
- 45
- 7,300
- In stock
- 10 mg
- 82
- 80
- 67
- 10,900
- In stock
- 25 mg
- 139
- 136
- 114
- 18,400
- In stock
- 50 mg
- 173
- 169
- 143
- 23,000
- In stock
- 100 mg
- 279
- 273
- 230
- 37,000
- In stock
- 200 mg
- 473
- 463
- 391
- 62,800
- In stock
- 300 mg
- 624
- 611
- 516
- 82,800
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 323.36
- C19H18FN3O
- [283173-50-2]
- This research compound is the free base form of rucaparib; please see the other form of rucaparib, Cat. No. [R-6399], Rucaparib Phosphate, for further technical information about both of these research compounds. The phosphate salt form of rucaparib is used for some or all rucaparib formulations for use in humans.
- This rucaparib product is the free base, whose CAS number is given above. The CAS number of the phosphate salt form is 459868-92-9.
- Rucaparib (as the camsylate salt) is the active ingredient in the drug product sold under the trade name Rubraca®. This drug is currently approved in a least one country for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. NOTE: THE RUCAPARIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT RUBRACA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.